|本期目录/Table of Contents|

[1]王宇,刘超 综述,周旋 审校.PAI-1在肿瘤进展中的功能与机制探讨[J].天津医科大学学报,2024,30(01):96-100.[doi:10.20135/j.issn.1006-8147.2024.01.0096]
点击复制

PAI-1在肿瘤进展中的功能与机制探讨(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
30卷
期数:
2024年01期
页码:
96-100
栏目:
综述
出版日期:
2024-01-01

文章信息/Info

Title:
-
文章编号:
1006-8147(2024)01-0096-05
作者:
王宇; 刘超 综述; 周旋 审校
（天津医科大学肿瘤医院颌面耳鼻喉肿瘤科，国家恶性肿瘤临床医学研究中心，天津市肿瘤防治重点实验室，天津市恶性肿瘤临床医学研究中心，天津 300060）
Author(s):
-
关键词:
纤溶酶原激活物抑制剂-1; 肿瘤增殖; 肿瘤转移; 免疫微环境
Keywords:
-
分类号:
R73
DOI:
10.20135/j.issn.1006-8147.2024.01.0096
文献标志码:
A
摘要:
纤溶酶原激活物抑制剂-1（PAI-1）在多种类型肿瘤中异常表达，可作为预测肿瘤进展、复发的重要靶标应用于临床诊疗。研究表明，PAI-1受多种细胞因子调控，不仅参与肿瘤细胞黏附，诱导肿瘤微血管生成，促进肿瘤侵袭、转移，还促进肿瘤细胞增殖，重塑免疫微环境，从而影响抗肿瘤治疗效果。研究证明，PAI-1是一种极具潜力的肿瘤诊断与治疗的分子标志物。PAI-1在肿瘤侵袭转移、血管生成、肿瘤细胞增殖与凋亡以及免疫逃逸中具有重要作用，靶向PAI-1可能用于肿瘤的治疗。
Abstract:
-

参考文献/References:

[1] WANG B，GU B，ZHANG T，et al. Good or bad：paradox of plasmi-nogen activator inhibitor 1（PAI-1） in digestive system tumors [J]. Cancer Lett，2023，559：216117.
[2] LI S，WEI X，HE J，et al. Plasminogen activator inhibitor-1 in cancer research [J]. Biomed Pharmacother，2018，105：83-94.
[3] FUCHS A，SAMOVSKI D，SMITH G I，et al. Associations among adipose tissue immunology，inflammation，exosomes and insulin sensitivity in people with obesity and nonalcoholic fatty liver disease [J]. Gastroenterology，2021，161（3）：968-981.
[4] MCCANN J V，XIAO L，KIM D J，et al. Endothelial miR-30c suppresses tumor growth via inhibition of TGF-beta-induced Serpine1 [J]. J ClinInvest，2019，129（4）：1654-1670.
[5] LOOK M P，VAN PUTTEN W L，DUFFY M J，et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients[J]. J Natl Cancer Inst，2002，94（2）：116-128.
[6] PALMIROTTA R，FERRONI P，SAVONAROLA A，et al. Prognostic value of pre-surgical plasma PAI-1（plasminogen activator inhibitor-1） levels in breast cancer [J]. Thromb Res，2009，124（4）：403-408.
[7] FERRONI P，ROSELLI M，PORTARENA I，et al. Plasma plasminogen activator inhibitor-1（PAI-1） levels in breast cancer-relationship with clinical outcome[J]. Anticancer Res，2014，34（3）：1153-1161.
[8] LAMPELJ M，ARKO D，CAS-SIKOSEK N，et al. Urokinase plasminogen activator （uPA） and plasminogen activator inhibitor type-1（PAI-1） in breast cancer-correlation with traditional prognostic factors [J]. Radiol Oncol，2015，49（4）：357-364.
[9] KANEKO T，KONNO H，BABA M，et al. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer [J]. Cancer Sci，2003，94（1）：43-49.
[10] NISHIOKA N，MATSUOKA T，YASHIRO M，et al. Plasminogen activator inhibitor 1 RNAi suppresses gastric cancer metastasis in vivo [J]. Cancer Sci，2012，103（2）：228-232.
[11] CHIN D，BOYLE G M，WILLIAMS R M，et al. Novel markers for poor prognosis in head and neck cancer [J]. Int J Cancer，2005，113（5）：789-797.
[12] PAV?譫N M A，ARROYO-SOLERA I，T?魪LLEZ-GABRIEL M，et al. Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients[J]. Oncotarget，2015，6（30）：29016-29033.
[13] TZENG H T，YANG J L，TSENG Y J，et al. Plasminogen activator inhibitor-1 secretion by autophagy contributes to melanoma resistance to chemotherapy through tumor microenvironment modulation [J]. Cancers，2021，13（6）：1253.
[14] KIM W T，MUN J Y，BAEK S W，et al. Secretory SERPINE1 expression is increased by antiplatelet therapy，inducing MMP1 expression and increasing colon cancer metastasis[J]. Int J Mol Sci，2022，23（17）：9596.
[15] KUBALA M H，DECLERCK Y A. The plasminogen activator inhibitor-1 paradox in cancer：a mechanistic understanding[J]. Cancer Metastasis Rev，2019，38（3）：483-492.
[16] BIASELLA F，STRUNZ T，KIEL C，et al. Vitronectin and its interaction with PAI-1 suggests a functional link to vascular changes in AMD pathobiology [J]. Cells，2022，11（11）：1766.
[17] ZHANG W，YANG S，CHEN D，et al. SOX2-OT induced by PAI-1 promotes triple-negative breast cancer cells metastasis by sponging miR-942-5p and activating PI3K/Akt signaling[J]. Cell Mol Life Sci，2022，79（1）：59.
[18] WEI X，LI S，HE J，et al. Tumor-secreted PAI-1 promotes breast cancer metastasis via the induction of adipocyte-derived collagen remodeling [J]. Cell Commun and Signal，2019，17（1）：58.
[19] TSUGE M，OSAKI M，SASAKI R，et al. SK-216，a novel inhibitor of plasminogen activator inhibitor-1，suppresses lung metastasis of human osteosarcoma [J]. IntJ Mol Sci，2018，19（3）：736.
[20] CHUNG C L，WANG S W，MARTIN R，et al. Pentachloropseudilin inhibits transforming growth factor-beta （TGF-beta） activity by accelerating cell-surface type Ⅱ TGF-beta receptor turnover in target cells [J]. Chembiochem，2018，19（8）：851-864.
[21] LIN X，LIN B W，CHEN X L，et al. PAI-1/PIAS3/Stat3/miR-34a forms a positive feedback loop to promote EMT-mediated metastasis through Stat3 signaling in non-small cell lung cancer[J]. Biochem Biophys Res Commun，2017，493（4）：1464-1470.
[22] ZHANG W，XU J，FANG H，et al. Endothelial cells promote triple-negative breast cancer cell metastasis via PAI-1 and CCL5 signaling [J]. FASEB J，2018，32（1）：276-288.
[23] FURUYA H，HAYASHI K，SHIMIZU Y，et al. Plasminogen activator inhibitor-2 （PAI-2） overexpression supports bladder cancer development in PAI-1 knockout mice in N-butyl-N-（4-hydroxybutyl）-nitrosamine- induced bladder cancer mouse model[J]. J Transl Med，2020，18（1）：57.
[24] TAKAYAMA Y，HATTORI N，HAMADA H，et al. Inhibition of PAI-1 limits tumor angiogenesis regardless of angiogenic stimuli in malignant pleural mesothelioma[J]. Cancer Res，2016，76（11）：3285-3294.
[25] GEIS T，D?魻RING C，POPP R，et al. HIF-2alpha-dependent PAI-1 induction contributes to angiogenesis in hepatocellular carcinoma [J]. Exp Cell Res，2015，331（1）：46-57.
[26] GIACOIA E G，MIYAKE M，LAWTON A，et al. PAI-1 leads to G1-phase cell-cycle progression through cyclin D3/cdk4/6 upregulation [J]. Mol Cancer Res，2014，12（3）：322-334.
[27] YANG K，ZHANG S，ZHANG D，et al. Identification of SERPINE1，PLAU and ACTA1 as biomarkers of head and neck squamous cell carcinoma based on integrated bioinformatics analysis[J]. Int J Clin Oncol，2019，24（9）：1030-1041.
[28] CHE Y，WANG J，LI Y，et al. Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing che-moresistance[J]. Cell Death Dis，2018，9（7）：759.
[29] VALIENTE M，OBENAUF A C，JIN X，et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis[J]. Cell，2014，156（5）：1002-1016.
[30] YE Y，PENG L，VATTAI A，et al. Prostaglandin E2 receptor 3 （EP3） signaling promotes migration of cervical cancer via urokinase-type plasminogen activator receptor（uPAR）[J]. J Cancer Res Clin Oncol，2020，146（9）：2189-2203.
[31] WANG H C，LIN Y L，HSU C C，et al. Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8[J]. Theranostics，2019，9（24）：7168-7183.
[32] TSENG Y J，LEE C H，CHEN W Y，et al. Inhibition of PAI-1 blocks PD-L1 endocytosis and improves the response of melanoma cells to immune checkpoint blockade[J]. J Invest Dermatol，2021，141（11）：2690-2698.
[33] BAUMEIER C，ESCHER F，ALESHCHEVA G，et al. Plasminogen activator inhibitor-1 reduces cardiac fibrosis and promotes M2 ma-crophage polarization in inflammatory cardiomyopathy[J]. Basic Res Cardiol，2021，116（1）：1.
[34] KUBALA M H，PUNJ V，PLACENCIO-HICKOK V R，et al. Plasminogen activator inhibitor-1 promotes the recruitment and polarization of macrophages in cancer[J]. Cell Rep，2018，25（8）：2177-2191.
[35] ALBERTI C，PINCIROLI P，VALERI B，et al. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer[J]. Oncogene，2012，31（37）：4139-4149.
[36] WANG Q，LU W，YIN T，et al. Calycosin suppresses TGF-beta-induced epithelial-to-mesenchymal transition and migration by upregulating BATF2 to target PAI-1 via the Wnt and PI3K/Akt signaling pathways in colorectal cancer cells[J]. J Expe Clin Cancer Res，2019，38（1）：240.
[37] PAN X Y，WANG Y，SU J，et al. The mechanism and significance of synergistic induction of the expression of plasminogen activator inhibitor-1 by glucocorticoid and transforming growth factor beta in human ovarian cancer cells[J]. Mol Cell Endocrinol，2015，407：37-45.
[38] OH J W，OLMAN M，BENVENISTE E N. CXCL12-mediated induction of plasminogen activator inhibitor-1 expression in human CXCR4 positive astroglioma cells[J]. Biol Pharm Bull，2009，32（4）：573-537.
[39] BRYAN L，PAUGH B S，KAPITONOV D，et al. Sphingosine-1-pho-sphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells：implications for invasiveness[J]. Mol Cancer Res，2008，6（9）：1469-1477.
[40] TENG F，ZHANG J X，CHEN Y，et al. LncRNA NKX2-1-AS1 promotes tumor progression and angiogenesis via upregulation of SERPINE1 expression and activation of the VEGFR-2 signaling pathway in gastric cancer[J]. Mol Oncol，2021，15（4）：1234-1255.
[41] AKULA S M，RUVOLO P P，MCCUBREY J A. TP53/miR-34a-associated signaling targets SERPINE1 expression in human pancreatic cancer[J]. Aging，2020，12（3）：2777-2797.
[42] KIMURA D，IMAIZUMI T，TAMO W，et al. Hypoxia enhances the expression of plasminogen activator inhibitor-1 in human lung cancer cells，EBC-1[J]. Tohoku J Exp Med，2002，196（4）：259-267.
[43] ONER M G，ROKAVEC M，KALLER M，et al. Combined inactivation of TP53 and MIR34A promotes colorectal cancer development and progression in mice via increasing levels of IL6R and PAI1[J]. Gastroenterology，2018，155（6）：1868-1882.
[44] MASHIKO S，KITATANI K，TOYOSHIMA M，et al. Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer [J]. Cancer Biol Ther，2015，16（2）：253-260.
[45] BROOKS T D，WANG S W，BR?譈NNER N，et al. XR5967，a novel modulator of plasminogen activator inhibitor-1 activity，suppresses tumor cell invasion and angiogenesis in vitro[J]. Anticancer Drugs，2004，15（1）：37-44.
[46] NAKATSUKA E，SAWADA K，NAKAMURA K，et al. Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482，a novel plasminogen activator inhibitor-1 inhibitor，inhibits ovarian cancer peritoneal dissemination[J]. Oncotarget，2017，8（52）：89887-89902.

相似文献/References:

备注/Memo

备注/Memo:
基金项目 国家自然科学基金面上项目（82073010）；国家自然科学基金青年项目（82002892）；天津市教委科研计划项目（2019KJ188）；天津市医学重点学科(专科)建设项目(TJYXZDXK-009A)
作者简介 王宇（1991-），男，主治医师，博士，研究方向：头颈肿瘤；通信作者：周旋，E-mail：xuanzhou@tmu.edu.cn。
更新日期/Last Update: 2024-01-01